The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)
Abstract
OBJECTIVE: To undertake a multicentre epidemiological study reflecting acromegaly in Spain. DESIGN: Voluntary reporting of data on patients with acromegaly to an online database, by the managing physician. METHODS: Data on demographics, diagnosis, estimated date of initial symptoms and diagnosis, pituitary imaging, visual fields, GH and IGF-I concentrations (requested locally), medical, radiotherapy and neurosurgical treatments, morbidity and mortality were collected. RESULTS: Data were included for 1219 patients (60.8% women) with a mean age at diagnosis of 45 years (s.d. 14 years). Reporting was maximal in 1997 (2.1 cases per million inhabitants (c.p.m.) per year); prevalence was globally 36 c.p.m., but varied between 15.7 and 75.8 c.p.m. in different regions. Of 1196 pituitary tumours, most were macroadenomas (73%); 81% of these patients underwent surgery, 45% received radiotherapy and 65% were given medical treatment (somatostatin analogues in 68.3% and dopamine agonists in 31.4%). Cures (GH values (basal or after an oral glucose tolerance test) <2 ng/ml, normal IGF-I, or both) were observed in 40.3% after surgery and 28.2% after radiotherapy. Hypertension (39.1%), diabetes mellitus (37.6%), hypopituitarism (25.7%), goitre (22.4%), carpal tunnel syndrome (18.7%) and sleep apnoea (13.2%) were reported as most frequent morbidities; 6.8% of the patients had cancer (breast in 3.1% of the women and colon in 1.2% of the cohort). Fifty-six patients died at a mean age of 60 years (s.d. 14 years), most commonly of a cardiovascular cause (39.4%); mortality was greater in patients given radiotherapy (hazard ratio 2.29; 95% confidence interval 1.03 to 5.08; P=0.026), and in those in whom GH and IGF-I concentrations were never normal (P<0.001). CONCLUSIONS: This acromegaly registry offers a realistic overview of the epidemiological characteristics, treatment outcome and morbidity of acromegaly in Spain. As active disease and treatment with radiotherapy are associated with an increase in mortality, efforts to control the disease early are desirable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
Factors Influencing Mortality in Acromegaly
Holdaway, I. M., Rajasoorya, R. C., & Gamble, G. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031199 · Cited by 651
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
BENGTSSON, B., EDÉN, S., ERNEST, I., ODÉN, A., & SJÖGREN, B. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15881.x · Cited by 528
EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION
ALEXANDER, L., APPLETON, D., HALL, R., ROSS, W. M., & WILKINSON, R. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03135.x · Cited by 466
An audit of outcome of treatment in acromegaly
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068816 · Cited by 466
Holdaway, I. M., & Rajasoorya, C. (1999) · Pituitary · doi:10.1023/a:1009965803750 · Cited by 394
Ayuk, J., Clayton, R. N., Holder, G., Sheppard, M. C., Stewart, P. M., & Bates, A. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031584 · Cited by 343
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
Beauregard, C., Truong, U., Hardy, J., & Serri, O. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01679.x · Cited by 300
Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience
Ahmed, Elsheikh, Stratton, Page, Adams, & Wass (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00760.x · Cited by 291 · cited 1×
“Even in published series, cure rates vary tremendously and an inverse correlation has been found between the number of neurosurgeons operating in one centre and the cure rate (23, 26), varying between 37% and 91% for microadenomas ( 20 , 27).”
BackgroundAcromegaly and gastrointestinal cancer
Ron, E., Gridley, G., Hrubec, Z., Page, W., Arora, S., & Fraumeni, J. F. (1991) · Cancer · doi:10.1002/1097-0142(19911015)68:8<1673::aid-cncr2820680802>3.0.co;2-0 · Cited by 250
Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
Sheaves, R., Jenkins, P., Blackburn, P., Huneidi, A. H., Afshar, F., Medbak, S., Grossman, A. B., Besser, G. M., & Wass, J. A. H. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8370847.x · Cited by 199
Increased incidence of neoplasia in patients with pituitary adenomas
Popovic, V., Damjanovic, S., Micic, D., Nesovic, M., Djurovic, M., Petakov, M., Obradovic, S., Zoric, S., Simic, M., Penezic, Z., et al. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00536.x · Cited by 196
CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem?
Melmed, S. K. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.2929 · Cited by 196
CLINICAL PERSPECTIVE: Acromegaly and Cancer: A Problem
Jenkins, P. J. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.2935 · Cited by 189
Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in Acromegaly
Biermasz, N. R., Dulken, H. V., & Roelfsema, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.12.4596 · Cited by 181
Acromegaly: An epidemiological study
Etxabe, J., Gaztambide, S., Latorre, P., & Vazquez, J. A. (1993) · Journal of Endocrinological Investigation · doi:10.1007/bf03344942 · Cited by 177
Self-citationOutcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon
Gittoes, N. J. L. (1999) · QJM · doi:10.1093/qjmed/92.12.741 · Cited by 176
Pathogenesis and Prevalence of Hypertension in Acromegaly
Bondanelli, M., Ambrosio, M. R., & Uberti, E. C. D. (2001) · Pituitary · doi:10.1023/a:1020798430884 · Cited by 166
Lissett, Peacey, Laing, Tetlow, Davis, J. R., & Shalet, S. M. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00581.x · Cited by 148
Prevalence and Pathogenesis of Sleep Apnea and Lung Disease in Acromegaly
Fatti, L. M., Scacchi, M., Pincelli, A. I., Lavezzi, E., & Cavagnini, F. (2001) · Pituitary · doi:10.1023/a:1020702631793 · Cited by 114
The epidemiology of endocrine tumours.
Monson, J. P. (2000) · Endocrine Related Cancer · doi:10.1677/erc.0.0070029 · Cited by 101
The Birmingham pituitary database: auditing the outcome of the treatment of acromegaly
Jenkins, D. J. A., O'Brien, I. A. D., Johnson, A., SHAKESPEAR, R. A., Sheppard, M. C., & Stewart, P. M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02913.x · Cited by 87
Factors determining the long-term outcome of surgery for acromegaly
OSMAN, I. A., James, R., CHATTERJEE, S., MATHIAS, D., & Kendall-Taylor, P. (1994) · QJM · doi:10.1093/oxfordjournals.qjmed.a068874 · Cited by 63
Oncological Complications of Excess GH in Acromegaly
Webb, S. M., Casanueva, F. F., & Wass, J. A. H. (2002) · Pituitary · doi:10.1023/a:1022149300972 · Cited by 58
Self-citationPituitary surgery for acromegaly
Clayton, R. N., Stewart, P. M., Shalet, S. M., & Wass, J. A. H. (1999) · BMJ · doi:10.1136/bmj.319.7210.588 · Cited by 57
Should There Be Statistical Guidelines for Medical Research Papers?
O'Fallon, J. R., Dubey, S. D., Salsburg, D. S., Edmonson, J. H., Soffer, A., & Colton, T. (1978) · Biometrics · doi:10.2307/2530390 · Cited by 50
Cited by
Acromegaly: An Endocrine Society Clinical Practice Guideline
Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2700 · Cited by 1,786
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Guidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Mortality in Acromegaly: A Metaanalysis
Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A., & Vandenbroucke, J. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1191 · Cited by 517
Metadata
- Authors
- Mestron, A., Webb, S., Astorga, R., Benito, P., Catala, M., Gaztambide, S., Gomez, J., Halperin, I., Lucas-Morante, T., Moreno, B., Obiols, G., de Pablos, P., Paramo, C., Pico, A., Torres, E., Varela, C., Vazquez, J., Zamora, J., Albareda, M., & Gilabert, M.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-10-01
- Volume
- 151
- Issue
- 4
- Pages
- 439-446
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2157737658
- Cited by
- 387
- References
- 28
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.